7 research outputs found
EpsteinβBarr virus LMP1 oncogene polymorphism in tatar and slavic populations in Russian Federation impacting on some malignant tumours
Objective: To compare genetic structure of the main EpsteinβBarr virus (EBV) oncogene, latent membrane protein 1 (LMP1), in EBV strains circulating in two genetically distinct ethnic populations in Russian Federation, Tatars and Slavs, as well as assess an impact of diverse LMP1 variants on incidence and mortality rate for some malignant tumors partially associated with EBV infection. Materials and methods. Oral washing samples were collected from 60 ethnic Kazan Tatars and 65 ethnic Moscow Slavics. Carboxy-terminal nucleotide sequences (41 and 40 sequences, respectively) derived from hypervariable LMP1 gene region were amplified from EBV DNA samples. Next, final nucleotide sequences were translated into amino acid sequences and analyzed according to classification by Edwards et al. Results. Analysis of 41 and 40 LMP1 samples obtained from ethnic Kasan Tatars and ethnic Moscow Slavics, respectively, revealed significant difference in relevant amino acid structures. In particular, all LMP1 samples derived from Moscow Slavics were found to belong to the four protein variants: B95.8/A, Medβ, China1 and NC. Among them, low-transforming variant B95.8/A was dominant (82.5%). In contrast, solely 21 out of 41 LMP1 samples derived from ethnic Tatars were classified as B95.8/A, Medβ and China1 variants. Importantly, the percentage of low-transforming B95.8/A variant among ethnic Tatar samples was significantly lower compared to that one found in Moscow Slavics (29.3% vs. 82.5%). On the other hand, seven (17.1%) out of 20 other samples formed a unique protein mono group characterized by LMP1 amino acid sequence differed from that one available in the GenBank database. Such group of variants was designated as LMP1-TatK. The remaining 13 samples (31.7%) did not match either protein variants, thereby forming the βbeyond classificationβ (LMP1-TatBC) group. Conclusion. The data obtained suggest that various LMP1 variants exist in EBV strains persisting in ethnic Tatrs and ethnic Slavics examined in Russian Federation. It was also found that EBV strains isolated from ethnic Tatars contained a unique LMP1 gene variant encoding protein LMP1-TatK lacked in EBV strains derived from ethnic Moscow Slavics. Taking into account the genealogy of Tatars, it cannot be ruled out that EBV strain bearing LMP1-TatK variant represented ethnically specific EBV strain that might circulate many centuries ago among their historical human predecessors called Mongol-Tatar tribes. In addition, it was shown that the LMP1 variants in EBV strains isolated from ethnic Kazan Tatars and ethnic Moscow Slavics did not affect the incidence and mortality of different forms of cancer consisting of EBV-associated cases
Π Π°ΡΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π³Π΅Π½ΠΎΠ² HLA II Ρ Π±ΠΎΠ»ΡΠ½ΡΡ ΡΠ°ΠΊΠΎΠΌ Π½ΠΎΡΠΎΠ³Π»ΠΎΡΠΊΠΈ, Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌ Ρ Π²ΠΈΡΡΡΠΎΠΌ ΠΠΏΡΡΠ΅ΠΉΠ½Π°βΠΠ°ΡΡ, ΠΈ Π΄ΡΡΠ³ΠΈΠΌΠΈ ΠΎΠΏΡΡ ΠΎΠ»ΡΠΌΠΈ ΡΠΎΡΠΎΠ²ΠΎΠΉ ΠΏΠΎΠ»ΠΎΡΡΠΈ Π² Π ΠΎΡΡΠΈΠΈ
Background. It has been proved that for the nasopharyngeal carcinoma (NPC) the etiological agent is the EpsteinβBarr virus (EBV). Being an ubiquitous infection, EBV, under certain conditions, is able to display its oncogenic potential. Among a wide range of tumors associated with EBV, the NPC occupies a special place because it is characterized by a geographically and ethnically heterogeneous distribution, suggesting that in the pathogenesis of NPC, in addition to EBV, an important role is played by other factors, such as genetic predisposition to this neoplasm. Among known genetic factors influencing the frequency of NPC development, the human leukocyte antigen (HLA) complex occupies an important place, as it plays a central role in the presentation of viral antigens to the immune system. In Russia, the association of HLA alleles with the risk of EBV associated forms of NPC development and with development of other oral cavity tumors (OOCT), not associated with the virus, has not been studied. In the literature there are contradictory information about HLA genes, which determine the predisposition to the emergence of these tumors, and their role in the initiation and formation an immune response to EBV proteins.Objective: to study the distribution of the of DQA1-, DQB1-, DRB1-HLA class II gene variants associated with respectively the risk or resistance to the development of NPC and OOCT and with a high and low level of antibody response to EBV main proteins. A group of healthy persons served as a control.Materials and methods. Blood samples from 62 patients with NPC, 44 patients with OOCT, and as control, 300 healthy individuals, were used in the study. The blood serum samples of NPC and OOCT patients were tested for the presence of immunoglobulin classes G and A antibodies to capsid and early EBV antigens by indirect immunofluorescence. All serum samples of patients and healthy individuals were genotyped on HLA-DQA1, -DQB1 and -DRB1 by the method of multi-primer amplification by sequence-specific primers by real-time polymerase chain reaction.Results. In NPC patients, an increase in the frequency of HLA-DRB1*08 was found when compared with the frequency of a similar allele in healthy individuals (5.6 % vs 1.8 %; odds ratio (OR) 3.2; 95 % confidence interval (CI) 1.1β9.1; p = 0.02), and, on the contrary, a lower HLA-DQB1*0301 frequency was detected (16.1 % vs 25.3 %; p <0.05) than in healthy individuals. The data obtained suggest that the HLA-DRB1*08 gene is associated with an increased sensitivity to NPC.In OOCT patients, HLA-DQB1*0502β4 and HLA-DRB1*16 variants were less common than in healthy individuals (1.1 % vs 6.8 %; p <0.05 and 1.1 % vs 6.7 %; OR 0.16; 95 % CI 0.01β1.08; p <0.05, respectively), suggesting that the HLA-DQB1*0301 gene is associated with resistance to NPC, and HLA-DQB1*0502β4 and HLA-DRB1*16 variants β with resistance to OOCT. It is interesting to note the difference in the frequency of HLA-DRB1*13 between NPC and OOCT patients (17.7 % vs 6.8 %; OR 2.9; 95 %CI 1.1β8.6; p <0.05). One can suggest that this difference is related to the proven involvement of EBV in the NPC development. There were no other differences in the frequencies of class II HLA genes between the groups of NPC and OOCT patients. For the first time in Russia the importance of alleles DQA1, DQB1 and DRB1 of the HLA gene for the NPC and OOCT development, malignant tumors, respectively associated and non-associated with EBV, was studied. The results of the investigation completed together with known literature data allow us to conclude that the above alleles of the HLA class II gene can serve as a factor predisposing to the development of NPC in Russia.Conclusion. However, in order to establish a strict association between a specific HLA haplotype and the NPC and OOCT incidence, the information obtained is insufficient due to the complexity and variability of the genetic control of immune responses controlling the tumor process. A comprehensive study of this issue using different immune response genes and populations of different ethnic origins will probably help to elucidate the effect of genetic polymorphism on the risk of NPC and OOCT development in Russia.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠΠ°Π·ΠΎΡΠ°ΡΠΈΠ½Π³Π΅Π°Π»ΡΠ½Π°Ρ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΠ° (ΡΠ°ΠΊ Π½ΠΎΡΠΎΠ³Π»ΠΎΡΠΊΠΈ, Π ΠΠ), ΠΊΠ°ΠΊ ΠΈΠ·Π²Π΅ΡΡΠ½ΠΎ, ΡΡΡΠΎΠ³ΠΎ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π° Ρ Π²ΠΈΡΡΡΠΎΠΌ ΠΠΏΡΡΠ΅ΠΉΠ½Π°βΠΠ°ΡΡ (ΠΠΠ). ΠΠ΄Π½Π°ΠΊΠΎ ΠΠΠ ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΠ±ΠΈΠΊΠ²ΠΈΡΠ°ΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠ΅ΠΉ, ΡΠΎΠ³Π΄Π° ΠΊΠ°ΠΊ Π ΠΠ ΡΠ°Π·Π²ΠΈΠ²Π°Π΅ΡΡΡ Π΄ΠΎΠ²ΠΎΠ»ΡΠ½ΠΎ ΡΠ΅Π΄ΠΊΠΎ ΠΈ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΠ΅ΡΡΡ Π³Π΅ΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈ ΠΈ ΡΡΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π½Π΅ΠΎΠ΄Π½ΠΎΡΠΎΠ΄Π½ΡΠΌ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΠ΅ΠΌ, ΡΡΠΎ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΠΏΡΠ΅Π΄ΠΏΠΎΠ»ΠΎΠΆΠΈΡΡ Π²Π°ΠΆΠ½ΡΡ ΡΠΎΠ»Ρ Π΄ΡΡΠ³ΠΈΡ
ΠΊΠΎΡΠ°ΠΊΡΠΎΡΠΎΠ² Π² ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π΅ Π ΠΠ, ΡΠ°ΠΊΠΈΡ
ΠΊΠ°ΠΊ ΠΎΠΊΡΡΠΆΠ°ΡΡΠ°Ρ ΡΡΠ΅Π΄Π° ΠΈ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΏΡΠ΅Π΄ΡΠ°ΡΠΏΠΎΠ»ΠΎΠΆΠ΅Π½Π½ΠΎΡΡΡ. Π‘ΡΠ΅Π΄ΠΈ ΠΈΠ·Π²Π΅ΡΡΠ½ΡΡ
Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ°ΠΊΡΠΎΡΠΎΠ², Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Ρ Π ΠΠ, Π³Π»Π°Π²Π½ΡΠΉ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡ Π³ΠΈΡΡΠΎΡΠΎΠ²ΠΌΠ΅ΡΡΠΈΠΌΠΎΡΡΠΈ (Π»Π΅ΠΉΠΊΠΎΡΠΈΡΠ°ΡΠ½ΡΠΉ Π°Π½ΡΠΈΠ³Π΅Π½ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°, human leukocyte antigen (HLA)) Π·Π°Π½ΠΈΠΌΠ°Π΅Ρ Π²Π°ΠΆΠ½ΠΎΠ΅ ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΠ΅, ΡΠ°ΠΊ ΠΊΠ°ΠΊ ΠΈΠ³ΡΠ°Π΅Ρ ΠΊΠ»ΡΡΠ΅Π²ΡΡ ΡΠΎΠ»Ρ Π² ΠΏΡΠ΅Π·Π΅Π½ΡΠ°ΡΠΈΠΈ Π²ΠΈΡΡΡΠ½ΡΡ
Π°Π½ΡΠΈΠ³Π΅Π½ΠΎΠ² ΠΈΠΌΠΌΡΠ½Π½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ. Π Π ΠΎΡΡΠΈΠΈ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ Π°ΡΡΠΎΡΠΈΠ°ΡΠΈΠΈ Π°Π»Π»Π΅Π»Π΅ΠΉ HLA Ρ ΡΠΈΡΠΊΠΎΠΌ ΡΠ°Π·Π²ΠΈΡΠΈΡ Π ΠΠ, ΡΠ²ΡΠ·Π°Π½Π½ΠΎΠ³ΠΎ Ρ ΠΠΠ, Π½Π΅ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΎΡΡ, Π° Π² Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΠ΅ ΡΡΡΠ΅ΡΡΠ²ΡΡΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΡΠ΅ΡΠΈΠ²ΡΠ΅ ΡΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΎ ΡΠΎΠ»ΠΈ ΡΠ°Π·Π½ΡΡ
HLA-Π³Π΅Π½ΠΎΠ² ΠΊΠ°ΠΊ Π² Π²ΠΎΠ·Π½ΠΈΠΊΠ½ΠΎΠ²Π΅Π½ΠΈΠΈ ΠΈ ΡΠ°Π·Π²ΠΈΡΠΈΠΈ Π ΠΠ, ΡΠ°ΠΊ ΠΈ Π² ΠΈΠ½ΠΈΡΠΈΠ°ΡΠΈΠΈ ΠΈ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΡΡ
ΠΈΠΌΠΌΡΠ½Π½ΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ° ΠΊ Π±Π΅Π»ΠΊΠ°ΠΌ ΠΠΠ.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΡΠ°ΡΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ Π²Π°ΡΠΈΠ°Π½ΡΠΎΠ² DQA1-, DQB1-, DRB1-Π³Π΅Π½ΠΎΠ² HLA ΠΊΠ»Π°ΡΡΠ° II Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Π ΠΠ ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π΄ΡΡΠ³ΠΈΠΌΠΈ ΠΎΠΏΡΡ
ΠΎΠ»ΡΠΌΠΈ ΠΏΠΎΠ»ΠΎΡΡΠΈ ΡΡΠ° (ΠΠΠΠ ), Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌΠΈ ΠΈ Π½Π΅ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌΠΈ Ρ ΠΠΠ, Π² Π³ΡΡΠΏΠΏΠ°Ρ
Ρ Π²ΡΡΠΎΠΊΠΈΠΌ ΠΈ Π½ΠΈΠ·ΠΊΠΈΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ Π³ΡΠΌΠΎΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΠΌΠΌΡΠ½Π½ΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ° ΠΊ ΠΎΡΠ½ΠΎΠ²Π½ΡΠΌ Π±Π΅Π»ΠΊΠ°ΠΌ ΠΠΠ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΠΎΠΉ Π·Π΄ΠΎΡΠΎΠ²ΡΡ
Π»ΠΈΡ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΡΠ΅Π³ΠΎ Π² ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΎΡΠ»ΠΈ 62 Π±ΠΎΠ»ΡΠ½ΡΡ
Π½Π΅Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌ Π ΠΠ ΠΈ 44 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Ρ ΠΠΠΠ , Π° ΡΠ°ΠΊΠΆΠ΅ 300 Π·Π΄ΠΎΡΠΎΠ²ΡΡ
Π»ΠΈΡ. Π‘ΡΠ²ΠΎΡΠΎΡΠΊΠ° ΠΊΡΠΎΠ²ΠΈ Π²ΡΠ΅Ρ
Π±ΠΎΠ»ΡΠ½ΡΡ
Π±ΡΠ»Π° ΠΏΡΠΎΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½Π° Π½Π° Π½Π°Π»ΠΈΡΠΈΠ΅ Π°Π½ΡΠΈΡΠ΅Π» ΠΈΠΌΠΌΡΠ½ΠΎΠ³Π»ΠΎΠ±ΡΠ»ΠΈΠ½ΠΎΠ² ΠΊΠ»Π°ΡΡΠΎΠ² G ΠΈ Π ΠΊ ΠΊΠ°ΠΏΡΠΈΠ΄Π½ΠΎΠΌΡ ΠΈ ΡΠ°Π½Π½Π΅ΠΌΡ Π°Π½ΡΠΈΠ³Π΅Π½Π°ΠΌ ΠΠΠ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ Π½Π΅ΠΏΡΡΠΌΠΎΠΉ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ»ΡΠΎΡΠ΅ΡΡΠ΅Π½ΡΠΈΠΈ. ΠΡΠ΅ ΠΎΠ±ΡΠ°Π·ΡΡ Π³Π΅Π½ΠΎΡΠΈΠΏΠΈΡΠΎΠ²Π°Π½Ρ Π½Π° HLA-DQA1, -DQB1 ΠΈ -DRB1 Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΌΡΠ»ΡΡΠΈΠΏΡΠ°ΠΉΠΌΠ΅ΡΠ½ΠΎΠΉ Π°ΠΌΠΏΠ»ΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ ΡΠΈΠΊΠ²Π΅Π½Ρ-ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΏΡΠ°ΠΉΠΌΠ΅ΡΠ°ΠΌΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ Π² ΡΠ΅ΠΆΠΈΠΌΠ΅ ΡΠ΅Π°Π»ΡΠ½ΠΎΠ³ΠΎ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ ΡΠ°ΡΡΠΎΡΡ HLA-DRB1*08 Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π ΠΠ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΊΠΎΠ½ΡΡΠΎΠ»Π΅ΠΌ (5,6 % ΠΏΡΠΎΡΠΈΠ² 1,8 %; ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΡΠ°Π½ΡΠΎΠ² (ΠΠ¨) 3,2; 95 % Π΄ΠΎΠ²Π΅ΡΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΠΈΠ½ΡΠ΅ΡΠ²Π°Π» (ΠΠ) 1,1β9,1; Ρ = 0,02). ΠΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎ, Π³Π΅Π½ HLA-DRB1*08 Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½ Ρ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΠΎΠΉ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ ΠΊ Π ΠΠ. Π ΡΠΎ ΠΆΠ΅ Π²ΡΠ΅ΠΌΡ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π ΠΠ Π±ΡΠ»Π° Π²ΡΡΠ²Π»Π΅Π½Π° Π±ΠΎΠ»Π΅Π΅ Π½ΠΈΠ·ΠΊΠ°Ρ, ΡΠ΅ΠΌ Π² ΠΊΠΎΠ½ΡΡΠΎΠ»Π΅, ΡΠ°ΡΡΠΎΡΠ° HLA-DQB1*0301 (16,1 % ΠΏΡΠΎΡΠΈΠ² 25,3 %; Ρ <0,05). ΠΠ°ΡΠΈΠ°Π½Ρ HLA-DQB1*0502β4, Π½Π°ΠΎΠ±ΠΎΡΠΎΡ, ΡΠ΅ΠΆΠ΅ Π²ΡΡΡΠ΅ΡΠ°Π»ΡΡ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠΠΠ , ΡΠ΅ΠΌ Π² ΠΊΠΎΠ½ΡΡΠΎΠ»Π΅ (1,1 % ΠΏΡΠΎΡΠΈΠ² 6,8 %; Ρ <0,05). ΠΠ½Π°Π»ΠΎΠ³ΠΈΡΠ½ΡΠ΅ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ ΠΊΠ°ΡΠ°ΡΡΡΡ HLA-DRB1*16, ΡΠ°ΡΡΠΎΡΠ° ΠΊΠΎΡΠΎΡΠΎΠ³ΠΎ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠΠΠ Π±ΡΠ»Π° Π½ΠΈΠΆΠ΅, ΡΠ΅ΠΌ Π² ΠΊΠΎΠ½ΡΡΠΎΠ»Π΅ (1,1 % ΠΏΡΠΎΡΠΈΠ² 6,7 %; ΠΠ¨ 0,16; 95 % ΠΠ 0,01β1,08; Ρ <0,05), Ρ. Π΅. Π³Π΅Π½ HLA-DQB1*0301 Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½ Ρ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΡΡ ΠΊ Π ΠΠ, Π° Π²Π°ΡΠΈΠ°Π½ΡΡ HLA-DQB1*0502β4 ΠΈ HLA-DRB1*16 β Ρ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΡΡ ΠΊ ΠΠΠΠ .ΠΠ½ΡΠ΅ΡΠ΅ΡΠ΅Π½ ΡΠ°ΠΊΡ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½ΠΈΡ ΡΠ°Π·Π»ΠΈΡΠΈΠΉ Π² ΡΠ°ΡΡΠΎΡΠ΅ HLA-DRB1*13 Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π ΠΠ ΠΈ ΠΠΠΠ (17,7 % ΠΏΡΠΎΡΠΈΠ² 6,8 %; ΠΠ¨ 2,9; 95 % ΠΠ 1,1β8,6; Ρ <0,05). ΠΡΠΈ ΡΠ°Π·Π»ΠΈΡΠΈΡ ΠΌΠΎΠ³ΡΡ Π±ΡΡΡ ΡΠ²ΡΠ·Π°Π½Ρ Ρ Π΄ΠΎΠΊΠ°Π·Π°Π½Π½ΡΠΌ ΡΡΠ°ΡΡΠΈΠ΅ΠΌ ΠΠΠ Π² ΡΠ°Π·Π²ΠΈΡΠΈΠΈ Π ΠΠ. ΠΡΡΠ³ΠΈΡ
ΡΠ°Π·Π»ΠΈΡΠΈΠΉ ΠΏΠΎ ΡΠ°ΡΡΠΎΡΠ°ΠΌ Π³Π΅Π½ΠΎΠ² HLA ΠΊΠ»Π°ΡΡΠ° II ΠΌΠ΅ΠΆΠ΄Ρ Π³ΡΡΠΏΠΏΠ°ΠΌΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π ΠΠ ΠΈ ΠΠΠΠ Π½Π΅ Π²ΡΡΠ²Π»Π΅Π½ΠΎ. ΠΠΏΠ΅ΡΠ²ΡΠ΅ Π² Π ΠΎΡΡΠΈΠΈ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΡΠ²ΡΠ·ΠΈ Π°Π»Π»Π΅Π»Π΅ΠΉ DQA1, DQB1 ΠΈ DRB1 Π³Π΅Π½Π° HLA Ρ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ΠΌ Π½Π°Π·ΠΎΡΠ°ΡΠΈΠ½Π³Π΅Π°Π»ΡΠ½ΠΎΠΉ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΡ (Π ΠΠ) ΠΈ ΠΠΠΠ , Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΈ Π½Π΅ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Ρ ΠΠΠ.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ°ΡΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π² ΡΠΎΠ²ΠΎΠΊΡΠΏΠ½ΠΎΡΡΠΈ Ρ ΡΠΆΠ΅ ΠΈΠ·Π²Π΅ΡΡΠ½ΡΠΌΠΈ Π΄Π°Π½Π½ΡΠΌΠΈ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡ Π·Π°ΠΊΠ»ΡΡΠΈΡΡ, ΡΡΠΎ ΠΈΠΌΠ΅Π΅ΡΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π½Π°Ρ ΡΠ²ΡΠ·Ρ Π³Π΅Π½ΠΎΠ² HLA ΠΊΠ»Π°ΡΡΠ° II c ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ΠΌ Π ΠΠ, ΠΎΠ΄Π½Π°ΠΊΠΎ Π΄Π»Ρ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ ΡΡΡΠΎΠ³ΠΎΠΉ Π°ΡΡΠΎΡΠΈΠ°ΡΠΈΠΈ Π°Π»Π»Π΅Π»Π΅ΠΉ HLA ΠΊΠ»Π°ΡΡΠ° II Ρ Π ΠΠ ΠΈ Π΄ΡΡΠ³ΠΈΠΌΠΈ ΠΎΠΏΡΡ
ΠΎΠ»ΡΠΌΠΈ ΠΎΠ±Π»Π°ΡΡΠΈ Π³ΠΎΠ»ΠΎΠ²Ρ ΠΈ ΡΠ΅ΠΈ ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΡ
ΡΠ²Π΅Π΄Π΅Π½ΠΈΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ ΠΈΠ·-Π·Π° ΡΠ»ΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΈ Π²Π°ΡΠΈΠ°Π±Π΅Π»ΡΠ½ΠΎΡΡΠΈ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ ΠΈΠΌΠΌΡΠ½Π½ΡΡ
ΡΠ΅Π°ΠΊΡΠΈΠΉ, ΠΊΠΎΠ½ΡΡΠΎΠ»ΠΈΡΡΡΡΠΈΡ
ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΠΉ ΠΏΡΠΎΡΠ΅ΡΡ
ΠΠΈΡΡΡ ΠΠΏΡΡΠ΅ΠΉΠ½Π°-ΠΠ°ΡΡ Ρ Π°Π΄ΡΠ³Π΅ΠΉΡΠ΅Π² ΠΈ ΡΠ»Π°Π²ΡΠ½ Π² Π ΠΎΡΡΠΈΠΈ: ΡΠΈΠΏΡ Π²ΠΈΡΡΡΠ°, Π²Π°ΡΠΈΠ°Π½ΡΡ LMP1 ΠΈ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠ΅ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ
Introduction. It is known that the structural features of the Epstein-Barr virus (EBV) affect the manifestation of its biological properties. Based on differences in the sequences of the EBNA2, EBNA3A, -B, and -C genes, two types of the virus, EBV-1 and EBV-2, have been identified that have different ability to transform B cells in vitro and possibly playing certain role in the development of EBV-associated neoplasms.Aim. To study the prevalence of EBV-1 and EBV-2 in two ethnic groups, Πdygeans and Slavs, as well as the contribution of EBV-associated tumors to the overall incidence of malignant neoplasms certain organs and tissues.Materials and methods. DNA samples were extracted from 59 oral lavages of ethnic Πdygeans from Republic of Adygea and 40 such from oral cavity of ethnic Slavs of Moscow city. These samples were used for amplification of EBV DNA, determination of the concentration of viral DNA copies per 1 cell washout, as well as for amplification of EBV LMP1 followed by sequencing of the resulting gene samples and determination of their protein variant (LMP1).Results. Studies have shown that among the representatives of the Πdygeans the 2nd EBV type prevails, and among the Slavs, the 1st one. Epstein-Barr virus isolates in representatives of the two ethnic groups also differed in the structure of LMP1. Among the Slavs, a set of its LMP1 variants (B95.8/A, China, Med- and NC) was identified. However, among the Adygeans, the only variant - B95.8 and its subtype - B95.8/A was identified. EBV-1, which prevails among the representatives of the Slavs and has the ability to transform B-cells, was projected onto a higher incidence of tumors of the pharynx, stomach, Hodgkin's and non-Hodgkin's lymphomas (where EBV-associated cases cam occur) in the population of Moscow than in the population of the Republic of Adygea. However, the differences between incidence rates for these neoplasms (with the exception for the stomach tumors) were not statistically significant (p >0.5). A higher and statistically significantly different incidence rate of stomach cancer in residents of Moscow city, compared with that in residents of the Republic of Adygea, in our opinion, is not due to EBV-1 type and/or LMP1 variants, but rather is associated with a genetic predisposition the population of Moscow city to this tumor.Conclusion. The fact that two ethnic groups of Russia were found to be prevails by different types of EBV raises the question of their ethno-geographical association and their role in the induction of EBV-associated tumors. To resolve this issue additional studies in other geographical regions of Russia among representatives of different ethnic groups are required.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠΠ·Π²Π΅ΡΡΠ½ΠΎ, ΡΡΠΎ ΡΡΡΡΠΊΡΡΡΠ½ΡΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ Π²ΠΈΡΡΡΠ° ΠΠΏΡΡΠ΅ΠΉΠ½Π°-ΠΠ°ΡΡ (ΠΠΠ) Π²Π»ΠΈΡΡΡ Π½Π° ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠ΅ Π΅Π³ΠΎ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ²ΠΎΠΉΡΡΠ². ΠΠ° ΠΎΡΠ½ΠΎΠ²Π΅ ΡΠ°Π·Π»ΠΈΡΠΈΠΉ Π² ΠΏΠΎΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ
Π³Π΅Π½ΠΎΠ² EBNA2, EBNA3A, -B ΠΈ -C ΠΈΠ΄Π΅Π½ΡΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Ρ 2 ΡΠΈΠΏΠ° Π²ΠΈΡΡΡΠ°, 1-ΠΉ (ΠΠΠ-1) ΠΈ 2-ΠΉ (ΠΠΠ-2), ΠΎΠ±Π»Π°Π΄Π°ΡΡΠΈΠ΅ ΡΠ°Π·Π½ΠΎΠΉ ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΡΡ ΡΡΠ°Π½ΡΡΠΎΡΠΌΠΈΡΠΎΠ²Π°ΡΡ Π-ΠΊΠ»Π΅ΡΠΊΠΈ in vitro ΠΈ, Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎ, ΠΈΠ³ΡΠ°ΡΡΠΈΠ΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π½ΡΡ ΡΠΎΠ»Ρ Π² Π²ΠΎΠ·Π½ΠΈΠΊΠ½ΠΎΠ²Π΅Π½ΠΈΠΈ ΠΠΠ-Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ - ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΠΈ ΠΠΠ-1 ΠΈ Π²ΠΠ-2 Ρ 2 ΡΡΠ½ΠΎΡΠΎΠ², Π°Π΄ΡΠ³Π΅ΠΉΡΠ΅Π² ΠΈ ΡΠ»Π°Π²ΡΠ½, Π° ΡΠ°ΠΊΠΆΠ΅ Π²ΠΊΠ»Π°Π΄Π° Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Ρ ΠΠΠ ΡΠ»ΡΡΠ°Π΅Π² Π² ΠΎΠ±ΡΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΡ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΌΠΈ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡΠΌΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π½ΡΡ
ΠΎΡΠ³Π°Π½ΠΎΠ² ΠΈ ΡΠΊΠ°Π½Π΅ΠΉ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ· 59 ΡΠΌΡΠ²ΠΎΠ² ΠΏΠΎΠ»ΠΎΡΡΠΈ ΡΡΠ° ΡΡΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
Π°Π΄ΡΠ³Π΅ΠΉΡΠ΅Π² Π Π΅ΡΠΏΡΠ±Π»ΠΈΠΊΠΈ ΠΠ΄ΡΠ³Π΅Ρ ΠΈ 40 ΡΠ°ΠΊΠΎΠ²ΡΡ
ΡΡΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ»Π°Π²ΡΠ½ ΠΠΎΡΠΊΠ²Ρ ΡΠΊΡΡΡΠ°Π³ΠΈΡΠΎΠ²Π°Π»ΠΈ ΠΎΠ±ΡΠ°Π·ΡΡ ΠΠΠ. ΠΡΠΈ ΠΎΠ±ΡΠ°Π·ΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ Π΄Π»Ρ Π°ΠΌΠΏΠ»ΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ ΠΠΠ ΠΠΠ, ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ ΠΊΠΎΠΏΠΈΠΉ Π²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΠΠ Π½Π° 1 ΠΊΠ»Π΅ΡΠΊΡ ΡΠΌΡΠ²Π°, Π° ΡΠ°ΠΊΠΆΠ΅ Π΄Π»Ρ Π°ΠΌΠΏΠ»ΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ LMP1 ΠΠΠ Ρ ΠΏΠΎΡΠ»Π΅Π΄ΡΡΡΠΈΠΌ ΡΠ΅ΠΊΠ²Π΅Π½ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΡ
ΠΎΠ±ΡΠ°Π·ΡΠΎΠ² Π³Π΅Π½Π° ΠΈ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ ΠΈΡ
Π±Π΅Π»ΠΊΠΎΠ²ΠΎΠ³ΠΎ Π²Π°ΡΠΈΠ°Π½ΡΠ° (LMP1).Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΈ, ΡΡΠΎ Ρ ΠΏΡΠ΅Π΄ΡΡΠ°Π²ΠΈΡΠ΅Π»Π΅ΠΉ Π°Π΄ΡΠ³Π΅ΠΉΡΠ΅Π² ΠΏΡΠ΅ΠΎΠ±Π»Π°Π΄Π°Π΅Ρ ΠΠΠ-2, Π° Ρ ΡΠ»Π°Π²ΡΠ½ - ΠΠΠ-1. ΠΈΠ·ΠΎΠ»ΡΡΡ ΠΠΠ Ρ ΠΏΡΠ΅Π΄ΡΡΠ°Π²ΠΈΡΠ΅Π»Π΅ΠΉ 2 ΡΡΠ½ΠΎΡΠΎΠ² ΡΠ°ΠΊΠΆΠ΅ ΡΠ°Π·Π»ΠΈΡΠ°Π»ΠΈΡΡ ΠΏΠΎ ΡΡΡΡΠΊΡΡΡΠ΅ Π΅Π³ΠΎ LMP1: Ρ ΡΠ»Π°Π²ΡΠ½ Π²ΡΡΠ²Π»Π΅Π½ ΡΠ΅Π»ΡΠΉ Π½Π°Π±ΠΎΡ Π΅Π³ΠΎ Π±Π΅Π»ΠΊΠΎΠ²ΡΡ
Π²Π°ΡΠΈΠ°Π½ΡΠΎΠ² ( Π95.8/Π, China, Med- ΠΈ NC), Π° Ρ Π°Π΄ΡΠ³Π΅ΠΉΡΠ΅Π² - Π΅Π΄ΠΈΠ½ΡΡΠ²Π΅Π½Π½ΡΠΉ Π²Π°ΡΠΈΠ°Π½Ρ - B95.8 ΠΈ Π΅Π³ΠΎ ΠΏΠΎΠ΄ΡΠΈΠΏ -B95.8/A. Π΄ΠΎΠΌΠΈΠ½ΠΈΡΡΡΡΠΈΠΉ Ρ ΠΏΡΠ΅Π΄ΡΡΠ°Π²ΠΈΡΠ΅Π»Π΅ΠΉ ΡΠ»Π°Π²ΡΠ½ ΠΠΠ-1, ΠΎΠ±Π»Π°Π΄Π°ΡΡΠΈΠΉ ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΡΡ ΡΡΠ°Π½ΡΡΠΎΡΠΌΠΈΡΠΎΠ²Π°ΡΡ Π²-ΠΊΠ»Π΅ΡΠΊΠΈ, ΠΏΡΠΎΠ΅ΡΠΈΡΠΎΠ²Π°Π»ΡΡ Π½Π° Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΡΡ Ρ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ ΠΠΎΡΠΊΠ²Ρ, ΡΠ΅ΠΌ Ρ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ Π Π΅ΡΠΏΡΠ±Π»ΠΈΠΊΠΈ ΠΠ΄ΡΠ³Π΅Ρ, Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΡ ΠΎΠΏΡΡ
ΠΎΠ»ΡΠΌΠΈ Π³Π»ΠΎΡΠΊΠΈ, ΠΆΠ΅Π»ΡΠ΄ΠΊΠ°, Π»ΠΈΠΌΡΠΎΠΌΠΎΠΉ Π₯ΠΎΠ΄ΠΆΠΊΠΈΠ½Π° ΠΈ Π½Π΅Ρ
ΠΎΠ΄ΠΆΠΊΠΈΠ½ΡΠΊΠΈΠΌΠΈ Π»ΠΈΠΌΡΠΎΠΌΠ°ΠΌΠΈ, Π² ΠΊΠΎΡΠΎΡΡΡ
Π²ΡΡΡΠ΅ΡΠ°ΡΡΡΡ ΠΠΠ-Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ ΡΠ»ΡΡΠ°ΠΈ. ΠΠ΄Π½Π°ΠΊΠΎ ΡΠ°Π·Π»ΠΈΡΠΈΡ ΠΌΠ΅ΠΆΠ΄Ρ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΠΈ Π΄Π»Ρ ΡΠΊΠ°Π·Π°Π½Π½ΡΡ
ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΉ (Π·Π° ΠΈΡΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅ΠΌ Π΄Π°Π½Π½ΡΡ
Π΄Π»Ρ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ°) Π±ΡΠ»ΠΈ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π½Π΅Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΡΠΌΠΈ (p >0,5). ΠΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΠΈΠΉ ΠΈ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ ΠΎΡΠ»ΠΈΡΠ°ΡΡΠΈΠΉΡΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Ρ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΠΈ ΡΠ°ΠΊΠΎΠΌ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ° Ρ ΠΆΠΈΡΠ΅Π»Π΅ΠΉ ΠΠΎΡΠΊΠ²Ρ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΡΠ°ΠΊΠΎΠ²ΡΠΌ Ρ ΠΆΠΈΡΠ΅Π»Π΅ΠΉ Π Π΅ΡΠΏΡΠ±Π»ΠΈΠΊΠΈ ΠΠ΄ΡΠ³Π΅Ρ, ΠΏΠΎ Π½Π°ΡΠ΅ΠΌΡ ΠΌΠ½Π΅Π½ΠΈΡ, Π½Π΅ ΠΎΠ±ΡΡΠ»ΠΎΠ²Π»Π΅Π½ ΠΠΠ-1 ΠΈ/ΠΈΠ»ΠΈ Π²Π°ΡΠΈΠ°Π½ΡΠ°ΠΌΠΈ LMP1, Π° ΡΠΊΠΎΡΠ΅Π΅ ΡΠ²ΡΠ·Π°Π½ Ρ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠ΅Π΄ΡΠ°ΡΠΏΠΎΠ»ΠΎΠΆΠ΅Π½Π½ΠΎΡΡΡΡ ΠΊ ΡΡΠΎΠΉ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ ΠΠΎΡΠΊΠ²Ρ.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π€Π°ΠΊΡ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½ΠΈΡ Ρ 2 ΡΡΠ½ΠΎΡΠΎΠ² Π ΠΎΡΡΠΈΠΈ ΠΏΡΠ΅Π²Π°Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΡΠΈΠΏΠΎΠ² ΠΠΠ ΠΏΠΎΠ΄Π½ΠΈΠΌΠ°Π΅Ρ Π²ΠΎΠΏΡΠΎΡ ΠΎΠ± ΠΈΡ
ΡΡΠ½ΠΎΠ³Π΅ΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°ΡΡΠΎΡΠΈΠ°ΡΠΈΠΈ ΠΈ ΡΠΎΠ»ΠΈ Π² ΠΈΠ½Π΄ΡΠΊΡΠΈΠΈ ΠΠΠ-Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ. Π΄Π»Ρ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΡΡΠΎΠ³ΠΎ Π²ΠΎΠΏΡΠΎΡΠ° Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π² Π΄ΡΡΠ³ΠΈΡ
Π³Π΅ΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ΅Π³ΠΈΠΎΠ½Π°Ρ
Π ΠΎΡΡΠΈΠΈ Ρ ΠΏΡΠ΅Π΄ΡΡΠ°Π²ΠΈΡΠ΅Π»Π΅ΠΉ ΡΠ°Π·Π½ΡΡ
ΡΡΠ½ΠΎΡΠΎΠ²
ΠΠΈΡΡΡ ΠΠΏΡΡΠ΅ΠΉΠ½Π°βΠΠ°ΡΡ Ρ ΡΡΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠ°ΡΠ°Ρ: ΠΈΠ½ΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΡΡΡ ΠΈ ΡΠΈΠΊΠ²Π΅Π½ΡΠ½ΡΠ΅ Π²Π°ΡΠΈΠ°Π½ΡΡ ΠΎΠ½ΠΊΠΎΠ³Π΅Π½Π° LMP1
Objective of the investigation was to study the infection of ethnic Tatars with the EpsteinβBarr virus (EBV) and to analyze the genetic structure of the oncogene of the virus, the latent membrane protein 1 (LMP1), in the virus strains of Tatar origin. Materials and methods. The materials for the study were samples of boucle flushes of 60 students from the Kazan State Medical University who are ethnic Tatars (Tatars no less than in the 3rd generation). Amplified from DNA of boucle flushes the nucleotide sequences of the LMP1 samples translated into DNA amino acid sequences, have undergone classification based on the well-known and widely used in literature the R.H. Edwards et al. classification. Results. The analysis of nucleotide and deductive amino acid sequences of the 41 LMP1 amplicons revealed their homology with only three gene variants from the R.H. Edwards et al. classification (1999): 95.8/A (29.3 %; 12/41), Medβ (14.6 %; 6/41) and China1 (7.3 %, 3/41).Β Such variants of LMP1 as Alaskan, Med+, ChinΠ°2, China3 and NC, were not found. Among the LMP1 samples of Tatar origin in 20 cases (48.8 %), the composition of the mutations found did not allow them to be assigned to any of the oncogene variants listed above. Out of this number, in 7 (17.1 %) cases a mono group of LMP1 samples was found, differing not only from representatives of the Slavs, inhabitants of the European part of Russia, but also from other Kazan samples, and was designated as LMP1-TatK. The remaining 13 samples of LMP1 (31.7 %), not belonging to any of the known classifications, formed the group designated by us as an LMP1 group beside the classification (LMP1BC). Conclusion. Continuation of the study of the molecular-biological and functional properties of LMP1 in TatK and BC groups, which constitute 48.8 % of the number of gene samples studied, and an analysis of the peculiarities of the ethnic Tatar genotype, will probably help to clarify whether certain EBV strains influence morbidity and mortality in Tatar population with malignant neoplasms, which include EBVassociated cases.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΠΈΠ½ΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΡΡΠΈ Π²ΠΈΡΡΡΠΎΠΌ ΠΠΏΡΡΠ΅ΠΉΠ½Π°βΠΠ°ΡΡ (ΠΠΠ) ΡΡΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ°ΡΠ°Ρ ΠΈ Π°Π½Π°Π»ΠΈΠ· Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΡΡΠΊΡΡΡΡ ΠΎΠ½ΠΊΠΎΠ³Π΅Π½Π° Π²ΠΈΡΡΡΠ°, Π»Π°ΡΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ ΠΌΠ΅ΠΌΠ±ΡΠ°Π½Π½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° 1 (LMP1), Π² ΡΡΠ°ΠΌΠΌΠ°Ρ
Π²ΠΈΡΡΡΠ° ΡΠ°ΡΠ°ΡΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΎΠΈΡΡ
ΠΎΠΆΠ΄Π΅Π½ΠΈΡ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠΌ Π΄Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ»ΡΠΆΠΈΠ»ΠΈ Π±ΡΠΊΠΊΠ°Π»ΡΠ½ΡΠ΅ ΡΠΌΡΠ²Ρ 60 ΡΡΡΠ΄Π΅Π½ΡΠΎΠ² ΠΠ°Π·Π°Π½ΡΠΊΠΎΠ³ΠΎ Π³ΠΎΡΡΠ΄Π°ΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠ³ΠΎ ΡΠ½ΠΈΠ²Π΅ΡΡΠΈΡΠ΅ΡΠ°, ΡΠ²Π»ΡΡΡΠΈΡ
ΡΡ ΡΡΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΡΠ°ΡΠ°ΡΠ°ΠΌΠΈ (Π½Π΅ ΠΌΠ΅Π½Π΅Π΅ ΡΠ΅ΠΌ Π² III ΠΏΠΎΠΊΠΎΠ»Π΅Π½ΠΈΠΈ). ΠΡΠ΄Π΅Π»Π΅Π½Π½ΡΡ ΠΈΠ· ΡΠΌΡΠ²ΠΎΠ² ΠΠΠ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ Π΄Π»Ρ Π°ΠΌΠΏΠ»ΠΈΡΠΈΠΊΠ°ΡΠΈ LMP1. ΠΠΌΠΏΠ»ΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ ΠΈΠ· ΠΠΠ Π±ΡΠΊΠΊΠ°Π»ΡΠ½ΡΡ
ΡΠΌΡΠ²ΠΎΠ² Π½ΡΠΊΠ»Π΅ΠΎΡΠΈΠ΄Π½ΡΠ΅ ΠΏΠΎΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΠΎΠ±ΡΠ°Π·ΡΠΎΠ² LMP1, ΡΡΠ°Π½ΡΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ Π² Π°ΠΌΠΈΠ½ΠΎΠΊΠΈΡΠ»ΠΎΡΠ½ΡΠ΅ ΠΏΠΎΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ, ΠΏΠΎΠ΄Π²Π΅ΡΠ³Π»ΠΈΡΡ ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΈΠ·Π²Π΅ΡΡΠ½ΠΎΠΉ ΠΈ ΡΠΈΡΠΎΠΊΠΎ ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠ΅ΠΌΠΎΠΉ Π² Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΠ΅ ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ R.H. Edwards ΠΈ ΡΠΎΠ°Π²Ρ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠ½Π°Π»ΠΈΠ· Π½ΡΠΊΠ»Π΅ΠΎΡΠΈΠ΄Π½ΡΡ
ΠΈ ΡΡΠ°Π½ΡΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π°ΠΌΠΈΠ½ΠΎΠΊΠΈΡΠ»ΠΎΡΠ½ΡΡ
ΠΏΠΎΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΠ½ΠΎΡΡΠ΅ΠΉ 41-Π³ΠΎ Π°ΠΌΠΏΠ»ΠΈΠΊΠΎΠ½Π° LMP1 Π²ΡΡΠ²ΠΈΠ» ΠΈΡ
Π³ΠΎΠΌΠΎΠ»ΠΎΠ³ΠΈΡ ΡΠΎΠ»ΡΠΊΠΎ Ρ 3 Π²Π°ΡΠΈΠ°Π½ΡΠ°ΠΌΠΈ Π³Π΅Π½Π° ΠΈΠ· ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ R.H. Edwards ΠΈ ΡΠΎΠ°Π²Ρ.: 95.8/Π (29,3 %; 12/41), Medβ (14,6 %; 6/41) ΠΈ China1 (7,3 %; 3/41). Π’Π°ΠΊΠΈΠ΅ Π²Π°ΡΠΈΠ°Π½ΡΡ LMP1, ΠΊΠ°ΠΊ Alaskan, Med+, ChinΠ°2, China3 ΠΈ NC, Π½Π΅ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Ρ. Π ΠΎΡΡΠ°Π»ΡΠ½ΡΡ
20 ΡΠ»ΡΡΠ°ΡΡ
(48,8 %) ΡΠΏΠ΅ΠΊΡΡ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Π½ΡΡ
ΠΌΡΡΠ°ΡΠΈΠΉ Π² ΠΎΠ±ΡΠ°Π·ΡΠ°Ρ
LMP1 ΡΠ°ΡΠ°ΡΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΎΠΈΡΡ
ΠΎΠΆΠ΄Π΅Π½ΠΈΡ Π½Π΅ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ» ΠΈΡ
ΠΎΡΠ½Π΅ΡΡΠΈ Π½ΠΈ ΠΊ ΠΎΠ΄Π½ΠΎΠΌΡ ΠΈΠ· ΠΏΠ΅ΡΠ΅ΡΠΈΡΠ»Π΅Π½Π½ΡΡ
Π²ΡΡΠ΅ Π²Π°ΡΠΈΠ°Π½ΡΠΎΠ² ΠΎΠ½ΠΊΠΎΠ³Π΅Π½Π°. ΠΠ· Π½ΠΈΡ
Π² 7 ΡΠ»ΡΡΠ°ΡΡ
(17,1 % Π²ΡΠ΅Ρ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΡΡ
ΠΎΠ±ΡΠ°Π·ΡΠΎΠ²) ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Π° ΠΌΠΎΠ½ΠΎΠ³ΡΡΠΏΠΏΠ° Π²Π°ΡΠΈΠ°Π½ΡΠΎΠ² LMP1, ΠΎΡΠ»ΠΈΡΠ°ΡΡΠ°ΡΡΡ Π½Π΅ ΡΠΎΠ»ΡΠΊΠΎ ΠΎΡ ΠΏΡΠ΅Π΄ΡΡΠ°Π²ΠΈΡΠ΅Π»Π΅ΠΉ ΡΠ»Π°Π²ΡΠ½, ΠΆΠΈΡΠ΅Π»Π΅ΠΉ Π΅Π²ΡΠΎΠΏΠ΅ΠΉΡΠΊΠΎΠΉ ΡΠ°ΡΡΠΈ Π ΠΎΡΡΠΈΠΈ, Π½ΠΎ ΠΈ ΠΎΡ Π΄ΡΡΠ³ΠΈΡ
ΠΊΠ°Π·Π°Π½ΡΠΊΠΈΡ
ΠΎΠ±ΡΠ°Π·ΡΠΎΠ², ΠΈ ΠΎΠ±ΠΎΠ·Π½Π°ΡΠ΅Π½Π½Π°Ρ Π½Π°ΠΌΠΈ, ΠΊΠ°ΠΊ LMP1-TatK. ΠΡΡΠ°Π»ΡΠ½ΡΠ΅ 13 ΠΎΠ±ΡΠ°Π·ΡΠΎΠ² LMP1 (31,7 %), Π½Π΅ ΠΎΡΠ½ΠΎΡΡΡΠΈΡ
ΡΡ Π½ΠΈ ΠΊ ΠΎΠ΄Π½ΠΎΠΉ ΠΈΠ· ΠΈΠ·Π²Π΅ΡΡΠ½ΡΡ
ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΉ, ΡΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π»ΠΈ Π³ΡΡΠΏΠΏΡ, ΠΎΠ±ΠΎΠ·Π½Π°ΡΠ΅Π½Π½ΡΡ Π½Π°ΠΌΠΈ, ΠΊΠ°ΠΊ Π³ΡΡΠΏΠΏΠ° LMP1 Π²Π½Π΅ ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ (LMP1ΠΠ). ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ°Π»ΡΠ½Π΅ΠΉΡΠ΅Π΅ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎ-Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΡΠ²ΠΎΠΉΡΡΠ² LMP1 Π² Π³ΡΡΠΏΠΏΠ°Ρ
ΠΠ ΠΈ TatK, ΡΠΎΡΡΠ°Π²Π»ΡΡΡΠΈΡ
48,8 % ΠΎΡ ΡΠΈΡΠ»Π° ΠΈΠ·ΡΡΠ΅Π½Π½ΡΡ
ΠΎΠ±ΡΠ°Π·ΡΠΎΠ² ΠΎΠ½ΠΊΠΎΠ±Π΅Π»ΠΊΠ°, ΠΈ Π°Π½Π°Π»ΠΈΠ· ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ Π³Π΅Π½ΠΎΡΠΈΠΏΠ° ΡΡΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ°ΡΠ°Ρ, Π²Π΅ΡΠΎΡΡΠ½ΠΎ, ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡ Π²ΡΡΡΠ½ΠΈΡΡ, ΠΎΠΊΠ°Π·ΡΠ²Π°ΡΡ Π»ΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π½ΡΠ΅ ΡΡΠ°ΠΌΠΌΡ ΠΠΠ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π½Π° ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΠΈ ΠΈ ΡΠΌΠ΅ΡΡΠ½ΠΎΡΡΠΈ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΌΠΈ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡΠΌΠΈ, Π² ΡΠΎΡΡΠ°Π² ΠΊΠΎΡΠΎΡΡΡ
Π²Ρ
ΠΎΠ΄ΡΡ ΠΠΠ-Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ ΡΠ»ΡΡΠ°ΠΈ, Ρ ΡΠ°ΡΠ°ΡΡΠΊΠΎΠ³ΠΎ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ
HLA II genes distribution in EpsteinβBarr virus-associated nasopharyngeal carcinoma and other tumors of the oral cavity patients in Russia
Background. It has been proved that for the nasopharyngeal carcinoma (NPC) the etiological agent is the EpsteinβBarr virus (EBV). Being an ubiquitous infection, EBV, under certain conditions, is able to display its oncogenic potential. Among a wide range of tumors associated with EBV, the NPC occupies a special place because it is characterized by a geographically and ethnically heterogeneous distribution, suggesting that in the pathogenesis of NPC, in addition to EBV, an important role is played by other factors, such as genetic predisposition to this neoplasm. Among known genetic factors influencing the frequency of NPC development, the human leukocyte antigen (HLA) complex occupies an important place, as it plays a central role in the presentation of viral antigens to the immune system. In Russia, the association of HLA alleles with the risk of EBV associated forms of NPC development and with development of other oral cavity tumors (OOCT), not associated with the virus, has not been studied. In the literature there are contradictory information about HLA genes, which determine the predisposition to the emergence of these tumors, and their role in the initiation and formation an immune response to EBV proteins.Objective: to study the distribution of the of DQA1-, DQB1-, DRB1-HLA class II gene variants associated with respectively the risk or resistance to the development of NPC and OOCT and with a high and low level of antibody response to EBV main proteins. A group of healthy persons served as a control.Materials and methods. Blood samples from 62 patients with NPC, 44 patients with OOCT, and as control, 300 healthy individuals, were used in the study. The blood serum samples of NPC and OOCT patients were tested for the presence of immunoglobulin classes G and A antibodies to capsid and early EBV antigens by indirect immunofluorescence. All serum samples of patients and healthy individuals were genotyped on HLA-DQA1, -DQB1 and -DRB1 by the method of multi-primer amplification by sequence-specific primers by real-time polymerase chain reaction.Results. In NPC patients, an increase in the frequency of HLA-DRB1*08 was found when compared with the frequency of a similar allele in healthy individuals (5.6 % vs 1.8 %; odds ratio (OR) 3.2; 95 % confidence interval (CI) 1.1β9.1; p = 0.02), and, on the contrary, a lower HLA-DQB1*0301 frequency was detected (16.1 % vs 25.3 %; p <0.05) than in healthy individuals. The data obtained suggest that the HLA-DRB1*08 gene is associated with an increased sensitivity to NPC.In OOCT patients, HLA-DQB1*0502β4 and HLA-DRB1*16 variants were less common than in healthy individuals (1.1 % vs 6.8 %; p <0.05 and 1.1 % vs 6.7 %; OR 0.16; 95 % CI 0.01β1.08; p <0.05, respectively), suggesting that the HLA-DQB1*0301 gene is associated with resistance to NPC, and HLA-DQB1*0502β4 and HLA-DRB1*16 variants β with resistance to OOCT. It is interesting to note the difference in the frequency of HLA-DRB1*13 between NPC and OOCT patients (17.7 % vs 6.8 %; OR 2.9; 95 %CI 1.1β8.6; p <0.05). One can suggest that this difference is related to the proven involvement of EBV in the NPC development. There were no other differences in the frequencies of class II HLA genes between the groups of NPC and OOCT patients. For the first time in Russia the importance of alleles DQA1, DQB1 and DRB1 of the HLA gene for the NPC and OOCT development, malignant tumors, respectively associated and non-associated with EBV, was studied. The results of the investigation completed together with known literature data allow us to conclude that the above alleles of the HLA class II gene can serve as a factor predisposing to the development of NPC in Russia.Conclusion. However, in order to establish a strict association between a specific HLA haplotype and the NPC and OOCT incidence, the information obtained is insufficient due to the complexity and variability of the genetic control of immune responses controlling the tumor process. A comprehensive study of this issue using different immune response genes and populations of different ethnic origins will probably help to elucidate the effect of genetic polymorphism on the risk of NPC and OOCT development in Russia
EpsteinβBarr virus in the ethnic Tatars population: the infection and sequence variants of LMP1 oncogene
Objective of the investigation was to study the infection of ethnic Tatars with the EpsteinβBarr virus (EBV) and to analyze the genetic structure of the oncogene of the virus, the latent membrane protein 1 (LMP1), in the virus strains of Tatar origin. Materials and methods. The materials for the study were samples of boucle flushes of 60 students from the Kazan State Medical University who are ethnic Tatars (Tatars no less than in the 3rd generation). Amplified from DNA of boucle flushes the nucleotide sequences of the LMP1 samples translated into DNA amino acid sequences, have undergone classification based on the well-known and widely used in literature the R.H. Edwards et al. classification. Results. The analysis of nucleotide and deductive amino acid sequences of the 41 LMP1 amplicons revealed their homology with only three gene variants from the R.H. Edwards et al. classification (1999): 95.8/A (29.3 %; 12/41), Medβ (14.6 %; 6/41) and China1 (7.3 %, 3/41).Β Such variants of LMP1 as Alaskan, Med+, ChinΠ°2, China3 and NC, were not found. Among the LMP1 samples of Tatar origin in 20 cases (48.8 %), the composition of the mutations found did not allow them to be assigned to any of the oncogene variants listed above. Out of this number, in 7 (17.1 %) cases a mono group of LMP1 samples was found, differing not only from representatives of the Slavs, inhabitants of the European part of Russia, but also from other Kazan samples, and was designated as LMP1-TatK. The remaining 13 samples of LMP1 (31.7 %), not belonging to any of the known classifications, formed the group designated by us as an LMP1 group beside the classification (LMP1BC). Conclusion. Continuation of the study of the molecular-biological and functional properties of LMP1 in TatK and BC groups, which constitute 48.8 % of the number of gene samples studied, and an analysis of the peculiarities of the ethnic Tatar genotype, will probably help to clarify whether certain EBV strains influence morbidity and mortality in Tatar population with malignant neoplasms, which include EBVassociated cases
ΠΠ°ΡΠΊΠ΅ΡΡ Π²ΠΈΡΡΡΠ° ΠΠΏΡΡΠ΅ΠΉΠ½Π°βΠΠ°ΡΡ Π² ΠΎΡΠ΅Π½ΠΊΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠΎΡΡΠΎΡΠ½ΠΈΡ ΡΠΎΡΡΠΈΠΉΡΠΊΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ ΡΠ°ΠΊΠΎΠΌ Π½ΠΎΡΠΎΠ³Π»ΠΎΡΠΊΠΈ
Introduction. EpsteinβBarr virus (EBV) is equally widespread in the endemic and non-endemic world regions for nasopharyngeal cancer (NPC). High incidence of NPC in endemic countries and low in non-endemic countries suggest there are different mechanisms and conditions for tumor occurrence and, possibly, different clinical significance of EBV-associated markers. However, significance of these markers for determining NPC in non-endemic regions is still poorly understood. Objective β to determine clinical significance of titers of IgG/IgA antibodies to EBV capsid antigen and concentrations of the viral DNA in patientsβ blood plasma as diagnostic and monitoring markers for NPC in a non-endemic region of Russia. Materials and methods. Titers of EB-specific antibodies were determined by indirect immunofluorescence, and concentration of the viral DNA in plasma was measured using a quantitative polymerase chain reaction in real time. Study group included patients with NPC (n = 96), and control group β blood donors (n = 171) and patients with other head and neck tumors (n = 33).Results. Titers of IgG/IgA antibodies to EBV capsid antigen, being an important diagnostic marker of nasopharyngeal cancer, did not always correlate with patientsβ clinical condition. Humoral response to emerging events often delayed due to inertia of the immune system. Concentration of EBV DNA in patientsβ blood plasma clearly reflected the dynamics of the pathological process: it decreased to background values in remission and increased while the disease progressed. In contrast to endemic regions, we did not find any correlation between the studied EBV markers and clinical manifestations of the disease, evaluated in accordance with the TNM classification (Tumor, Nodus and Metastasis).Conclusion. In non-endemic countries, such as Russia, serological and molecular markers of EBV can be successfully used for the primary diagnosis of NPC. However, for the disease monitoring, it is preferable to use the value of the concentrations of circulating EBV DNA, which, in contrast to the values of IgG/IgA antibody titers to VCA EBV, more accurately reflect the patientβs clinical condition.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅.Β Π ΡΠ½Π΄Π΅ΠΌΠΈΡΠ½ΡΡ
ΠΈ Π½Π΅ΡΠ½Π΄Π΅ΠΌΠΈΡΠ½ΡΡ
ΠΏΠΎ ΡΠ°ΠΊΡ Π½ΠΎΡΠΎΠ³Π»ΠΎΡΠΊΠΈ (Π ΠΠ) ΡΠ΅Π³ΠΈΠΎΠ½Π°Ρ
ΠΌΠΈΡΠ° Π² ΠΎΠ΄ΠΈΠ½Π°ΠΊΠΎΠ²ΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΠΈΡΠΎΠΊΠΎ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΎ ΠΈΠ½ΡΠΈΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ Π²ΠΈΡΡΡΠΎΠΌ ΠΠΏΡΡΠ΅ΠΉΠ½Π°βΠΠ°ΡΡ (ΠΠΠ). ΠΡΡΠΎΠΊΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΠΈ Π ΠΠ Π² ΡΠ½Π΄Π΅ΠΌΠΈΡΠ½ΡΡ
ΡΡΡΠ°Π½Π°Ρ
ΠΈ Π½ΠΈΠ·ΠΊΠΈΠ΅ Π² Π½Π΅ΡΠ½Π΄Π΅ΠΌΠΈΡΠ½ΡΡ
ΠΏΡΠ΅Π΄ΠΏΠΎΠ»Π°Π³Π°ΡΡ Π½Π°Π»ΠΈΡΠΈΠ΅ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΠΎΠ² ΠΈ ΡΡΠ»ΠΎΠ²ΠΈΠΉ Π²ΠΎΠ·Π½ΠΈΠΊΠ½ΠΎΠ²Π΅Π½ΠΈΡ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΈ, Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎ, ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΡΡ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ ΠΠΠ-Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² Π΄Π»Ρ Π΄Π°Π½Π½ΠΎΠ³ΠΎ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ. ΠΠ΄Π½Π°ΠΊΠΎ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ ΡΡΠΈΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² Π΄Π»Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ Π ΠΠ Π² Π½Π΅ΡΠ½Π΄Π΅ΠΌΠΈΡΠ½ΡΡ
ΡΠ΅Π³ΠΈΠΎΠ½Π°Ρ
Π΄ΠΎ ΡΠΈΡ
ΠΏΠΎΡ ΠΎΡΡΠ°Π΅ΡΡΡ ΠΌΠ°Π»ΠΎΠΈΠ·ΡΡΠ΅Π½Π½ΠΎΠΉ.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡΒ β ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΡΡ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ ΡΠΈΡΡΠΎΠ² IgG/IgA-Π°Π½ΡΠΈΡΠ΅Π» ΠΊ ΠΊΠ°ΠΏΡΠΈΠ΄Π½ΠΎΠΌΡ Π°Π½ΡΠΈΠ³Π΅Π½Ρ ΠΠΠ ΠΈ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΉ ΠΠΠ ΡΡΠΎΠ³ΠΎ Π²ΠΈΡΡΡΠ° Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³ΠΎΠ²ΡΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² Π ΠΠ Π² Π½Π΅ΡΠ½Π΄Π΅ΠΌΠΈΡΠ½ΠΎΠΌ ΡΠ΅Π³ΠΈΠΎΠ½Π΅ Π ΠΎΡΡΠΈΠΈ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ.Β ΡΠΈΡΡΡ ΠΠΠ-ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π°Π½ΡΠΈΡΠ΅Π» ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ Π½Π΅ΠΏΡΡΠΌΠΎΠΉ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ»ΡΠΎΡΠ΅ΡΡΠ΅Π½ΡΠΈΠΈ, Π° ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ Π²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΠΠ Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΈΠ·ΠΌΠ΅ΡΡΠ»ΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ Π² ΡΠ΅Π°Π»ΡΠ½ΠΎΠΌ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ. ΠΠ±ΡΠ΅ΠΊΡΠ°ΠΌΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΡΠ°Π»ΠΈ Π±ΠΎΠ»ΡΠ½ΡΠ΅ Π ΠΠ (nΒ = 96), Π° Π² Π³ΡΡΠΏΠΏΡ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ Π²ΠΎΡΠ»ΠΈ Π΄ΠΎΠ½ΠΎΡΡ ΠΊΡΠΎΠ²ΠΈ (nΒ = 171) ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Ρ Π΄ΡΡΠ³ΠΈΠΌΠΈ ΠΎΠΏΡΡ
ΠΎΠ»ΡΠΌΠΈ Π³ΠΎΠ»ΠΎΠ²Ρ ΠΈ ΡΠ΅ΠΈ (nΒ = 33).Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ.Β ΡΠΈΡΡΡ IgG/IgA-Π°Π½ΡΠΈΡΠ΅Π» ΠΊ ΠΊΠ°ΠΏΡΠΈΠ΄Π½ΠΎΠΌΡ Π°Π½ΡΠΈΠ³Π΅Π½Ρ ΠΠΠ, ΡΠ²Π»ΡΡΡΡ Π²Π°ΠΆΠ½ΡΠΌ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠΌ ΡΠ°ΠΊΠ° Π½ΠΎΡΠΎΠ³Π»ΠΎΡΠΊΠΈ, Π½Π΅ Π²ΡΠ΅Π³Π΄Π° ΠΊΠΎΡΡΠ΅Π»ΠΈΡΠΎΠ²Π°Π»ΠΈ Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠΎΡΡΠΎΡΠ½ΠΈΠ΅ΠΌ Π±ΠΎΠ»ΡΠ½ΡΡ
. ΠΡΠΌΠΎΡΠ°Π»ΡΠ½ΡΠΉ ΠΎΡΠ²Π΅Ρ Π½Π° Π²ΠΎΠ·Π½ΠΈΠΊΠ°ΡΡΠΈΠ΅ ΡΠΎΠ±ΡΡΠΈΡ ΡΠ°ΡΡΠΎ Π·Π°ΠΏΠ°Π·Π΄ΡΠ²Π°Π» ΠΈΠ·-Π·Π° ΠΈΠ½Π΅ΡΡΠΈΠΈ ΠΈΠΌΠΌΡΠ½Π½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ. ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΠΆΠ΅ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ ΠΠΠ ΠΠΠ Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΡΠ΅ΡΠΊΠΎ ΠΎΡΡΠ°ΠΆΠ°Π»ΠΈ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΡ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ°, ΡΠ½ΠΈΠΆΠ°Π»ΠΈΡΡ Π΄ΠΎ ΡΠΎΠ½ΠΎΠ²ΡΡ
Π·Π½Π°ΡΠ΅Π½ΠΈΠΉ Π² ΡΠΎΡΡΠΎΡΠ½ΠΈΠΈ ΡΠ΅ΠΌΠΈΡΡΠΈΠΈ ΠΈ Π²ΠΎΠ·ΡΠ°ΡΡΠ°Π»ΠΈ ΠΏΡΠΈ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ. Π ΠΎΡΠ»ΠΈΡΠΈΠ΅ ΠΎΡ ΡΠ½Π΄Π΅ΠΌΠΈΡΠ½ΡΡ
ΡΠ΅Π³ΠΈΠΎΠ½ΠΎΠ² ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΡ ΠΌΠ΅ΠΆΠ΄Ρ ΠΈΠ·ΡΡΠ°Π΅ΠΌΡΠΌΠΈ ΠΌΠ°ΡΠΊΠ΅ΡΠ°ΠΌΠΈ ΠΠΠ ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡΠΌΠΈ Π±ΠΎΠ»Π΅Π·Π½ΠΈ, ΠΎΡΠ΅Π½ΠΈΠ²Π°Π΅ΠΌΡΠΌΠΈ Π² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΠΈΠΈ Ρ ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΠ΅ΠΉ TNM (Tumor, Nodus and Metastasis), Π½Π°ΠΌΠΈ Π½Π΅ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Π°.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅.Β Π Π½Π΅ΡΠ½Π΄Π΅ΠΌΠΈΡΠ½ΡΡ
ΡΡΡΠ°Π½Π°Ρ
, ΡΠ°ΠΊΠΈΡ
ΠΊΠ°ΠΊ Π ΠΎΡΡΠΈΡ, ΡΠ΅ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΡΠ΅ ΠΌΠ°ΡΠΊΠ΅ΡΡ ΠΠΠ ΠΌΠΎΠ³ΡΡ Π±ΡΡΡ Ρ ΡΡΠΏΠ΅Ρ
ΠΎΠΌ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½Ρ Π΄Π»Ρ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ Π ΠΠ. ΠΠ΄Π½Π°ΠΊΠΎ Π΄Π»Ρ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π° Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Π»ΡΡΡΠ΅ ΠΏΡΠΈΠΌΠ΅Π½ΡΡΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ ΡΠΈΡΠΊΡΠ»ΠΈΡΡΡΡΠ΅ΠΉ ΠΠΠ ΠΠΠ, ΠΊΠΎΡΠΎΡΡΠ΅ Π² ΠΎΡΠ»ΠΈΡΠΈΠ΅ ΠΎΡ Π·Π½Π°ΡΠ΅Π½ΠΈΠΉ ΡΠΈΡΡΠΎΠ² IgG/IgA-Π°Π½ΡΠΈΡΠ΅Π» ΠΊ ΠΊΠ°ΠΏΡΠΈΠ΄Π½ΠΎΠΌΡ Π°Π½ΡΠΈΠ³Π΅Π½Ρ ΠΠΠ Π±ΠΎΠ»Π΅Π΅ ΡΠΎΡΠ½ΠΎ ΠΎΡΡΠ°ΠΆΠ°ΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΡΠΎΡΡΠΎΡΠ½ΠΈΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ²